Home
About
Overview
Management Team
Board of Directors
Technology
Overview
Posters
Pipeline
Overview
MT-3724
MT-5111
TAK-169
Clinical Trials
Overview
MT-3724 With Lenalidomide for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Active, not recruiting
MT-3724 for Relapsed or Refractory DLBCL
Active, not recruiting
MT-3724 With Gemcitabine and Oxaliplatin for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Active, not recruiting
MT-5111 in HER2-positive Solid Tumors
Recruiting
TAK-169 for Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
News & Media
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
Governance
Email Alerts
Contact
Careers
Events
News & Media
News & Media
Press Releases
Presentations
Events
3rd Annual Evercore ISI HealthCONx Conference
Dec 3, 2020 • 10:05 am EDT
Audio
Webcast
